NCT07650110Not yet recruiting
Biological Collection of the Rare Diseases of the Brain and Eye Vessels Cohort - 2
Collection Biologique de la Cohorte Des Maladies Rares Des Vaisseaux du Cerveau et de l'œil - 2
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry of Health since 2005. Since 2017, CERVCO has coordinated the MRVC cohort, a prospective cohort of patients with rare vascular diseases of the brain and retina, and established the associated B-MRVC biobank in 2020 to support translational research and biomarker discovery. Due to the rarity and heterogeneity of these disorders, centralized longitudinal collection of clinical data and biological samples is essential to improve understanding of disease mechanisms, identify biomarkers of progression and prognosis, and facilitate the development of new diagnostic and therapeutic approaches. The present study aims to expand this longitudinal biobank, enable national and international collaborative research through controlled sample sharing, and establish reference control samples to support biomarker validation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 10 Jun 2026
- Start date
- Jun 2026
- Primary completion date
- Jun 2038
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- NCT number
- NCT07650110
What you commit to
- Study type: Interventional
- Planned participants: 600
- From Jun 2026 to the primary completion date, Jun 2038
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute or chronic infectious disease
- Specific exclusion criteria for control subjects
- Known cardiovascular disease (coronary artery disease, arterial disease, atrial fibrillation, heart failure)
- Neurological history: stroke, TIA, intracranial haemorrhage, meningitis/encephalitis, head injury with loss of consciousness \>30 mins,
- Multiple sclerosis, neurodegenerative disease, active epilepsy,
- Diabetes
Other
- Common exclusion criteria for patients and control subjects:
- A person referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the Public Health Code, defined as:
- Pregnant women, women in labour or breastfeeding women
- Persons deprived of their liberty by judicial or administrative decision
- Persons hospitalised without consent and not subject to a legal protection measure, and persons admitted to a health or social care facility for purposes other than research
- Minors
- Adults subject to a legal protection measure (guardianship, curatorship or judicial protection), adults unable to give consent and not subject to a legal protection measure
- Individuals subject to a withdrawal period for another research study
- Patients participating in another interventional research study
- Any identified extra- or intracranial vascular pathology requiring specific management
- Current or former smoking (more than 10 pack-years)
- Antithrombotic or lipid-lowering treatment
Who the study is looking for
- For the group of patients with MVCR:
- Patients aged between 18 and 80 years at the time of inclusion
- Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL, or in another gene responsible for other forms of monogenic cSVD (such as the COL4A1, COL4A2 and HTRA1 genes) or a confirmed diagnosis of MOYA-MOYA (arteriography and/or genetic testing) or cavernoma, cerebral venous thrombosis or a cerebral vascular malformation, including cavernomas
- Covered by social security or an equivalent scheme
- Written consent.
- Patient included in the MVCR cohort For control group
- Subject aged between 18 and 80 at the time of inclusion.
- Written consent.
- Blood pressure \< 140/90 mmHg without treatment or \< 130/80 mmHg if treated and stable for ≥3 months
- Covered by social security or a similar scheme
- Strictly normal neurological examination (NIHSS=0; no focal deficit)
- Normal cognitive examination: MMSE ≥ 26
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.